Nikki M. Schultek

Nikki received her BS in Business Administration from Villanova University, studying Marketing, French and International Business. She began her career in industry with Pfizer and Genentech. Shortly after accepting her most treasured role, “mom”, Nikki fell systemically ill, including frightening neurodegenerative symptoms. After being diagnosed with Lyme Disease, Chlamydia pneumoniae and other co-infections and receiving antibiotic therapy, she experienced remission. Since 2017 Nikki has been accelerating innovation in Infection Associated Chronic Conditions and Illnesses (IACCIs), such as Alzheimer’s Disease, other neurological and psychiatric diseases, Asthma, and others by building interdisciplinary research collaborations. First, she Founded Intracell Research Group, LLC, uniting researchers, clinicians, and stakeholders across the globe to form cutting-edge research collaborations. She then Co-Founded the Alzheimer’s Pathobiome Initiative (AlzPI) and is serving as Executive Director. In 2024 Nikki also became the Founding Director of the New Pathobiome Research Center at the Philadelphia College of Osteopathic Medicine (PCOM) and President of the new CureChronic Disease Foundation, Inc. (501c3 pending). She serves as a co-investigator of a, 3,200-patient asthma trial (iTREAT-PC) and Guest Editor of a special issue on infections for the Springer Nature Journal "Molecular Neurobiology" between 2023 and 2025. Nikki served as co-lead author of the landmark AlzPI research roadmap “Establishment of a consensus protocol to explore the brain pathobiome in patients with mild cognitive impairment and Alzheimer's disease: Research outline and call for collaboration” published with the AlzPI and Intracell Research Group global teams in June 2023 in Alzheimer’s and Dementia: The Journal of the Alzheimer’s Association.